Mike Hennessy Jr. is the Chairman and CEO of 

Mike Hennessy Jr.

 has been the voice for practical, real-world strategy. We make complex breakthroughs professionally applicable, and we fundamentally drive advanced development and manufacturing every day.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

We earned our place as the market leader by creating uniquely expert content and engaging media platforms. Through 2025, we developed a bold, new look and content strategy. The design is incredible and we’re excited for you to experience it.

Our content authority comes from alignment with top experts across the field. By staying united with key opinion leaders in pharma, we can deliver impartial and objective insights. Our new media strategy elevates these stars, giving them the spotlight they deserve.

For more than 25 years, the official name has been 

. You do, too. Everyone does. Why? It’s precise. Gets right to the point. It’s picture-perfect for our approach to the industry.

Call us humble. We earned #1, and we focus on excellence. But this industry is defined by competition. So, we’re putting on the gloves as the comprehensive leader in engagement with key decision-makers in pharma and biopharma. Reach, quality, versatility—always.

Mike Hennessy Jr
President and CEO
MJH Life Sciences

Articles

Bold vision. Grand scale.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

The pharmaceutical sector continues to evolve at a remarkable pace, shaped by scientific breakthroughs, growing operational complexity, and heightened regulatory expectations. This issue highlights the industry’s ongoing effort to balance innovation with control—ensuring that as technologies and therapeutic modalities advance, manufacturing and quality systems advance alongside them.

Our cover story, “How a ‘Plan, Prevent, Prove’ Approach Helps Avoid Facility and Equipment Problems,” captures a core challenge for good manufacturing practice operations today: anticipating failure before it occurs. As facilities become more interconnected and equipment more sophisticated, risk-based planning and disciplined maintenance have become essential.

On the development front, Cynthia A. Challener, PhD, examines the increasingly complex world of highly potent APIs in “Trends and Challenges Impacting Highly Potent API Development.” The rising demand for targeted and potent therapies is driving investment in containment technologies, specialized infrastructure, and new approaches to worker and product safety. These pressures are reshaping how companies think about HPAPI innovation and scale-up.

Challener also explores the manufacturing implications of these shifts in “Leap Forward in Automation Anticipated for Small-Molecule Drug Product Manufacturing.” With formulation complexity growing and the need for efficiency intensifying, small-molecule manufacturers are turning to automation to reduce manual operations, enhance consistency, and streamline production timelines.

In “How Therapeutic and Analytical Advancements Help Drug Substance Testing Evolve,” Patrick Lavery highlights how advances in both therapies and technologies are redefining modern analytical strategies. He explores trends in sustainability, stability testing, and the emerging role of artificial intelligence in quality assessment. Rounding out the issue, the Ask the Expert feature offers an overview of batch recovery fundamentals, an essential reminder that strong foundational practices remain critical, even as the industry embraces new tools and capabilities. Together, these articles reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

Mike Hennessy Jr is Chairman and CEO of MJH Life Sciences®.

®
Vol. 49, No. 9
November/December 2025
Page: 8

When referring to this article, please cite it as Hennessy, M. How Innovation and Risk Management Are Reshaping Modern Drug Manufacturing. 

The pharmaceutical industry is rapidly evolving, driven by scientific advancements, operational complexities, and regulatory demands. Balancing innovation with control is crucial as technologies and therapeutic modalities progress. Key challenges include anticipating equipment failures and adapting to the complexities of highly potent APIs. Automation is becoming essential in small-molecule drug manufacturing to enhance efficiency and consistency. Advances in therapies and technologies are reshaping analytical strategies, with sustainability and AI playing significant roles. Despite these innovations, foundational practices like batch recovery remain vital for safe and reliable pharmaceutical production.

The articles in this issue reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

How Innovation and Risk Management Are Reshaping Modern Drug Manufacturing

Each new chapter in pharmaceutical innovation underscores a simple truth: the path from molecule to medicine is never linear. Scientific discovery, technological evolution, and market demands constantly reshape the landscape, requiring both agility and vision from every stakeholder. This issue of 

 captures the state of that journey, one that is as much about mastering fundamentals as it is about embracing new tools and approaches. Our cover story, “The Evolving Science Behind Formulation Development,” explores strategies across the drug product lifecycle. Vaibhav Sihorkar, PhD, of Aragen Life Sciences, offers insights into problem solving, the role of digital tools, and how geopolitical change is influencing formulation decisions from a CRDMO’s perspective. The complex area of drug formulation is further explored in “Personalized and Patient-Centric Administration of Oral Medicines,” which highlights how individualized therapies are moving forward despite the challenges of scalability and regulation.

On the business front, Ana Ali of RCK Partners provides a perspective on R&D tax relief in the United Kingdom, and Cheryl Barton, PharmaVision, hightlights the companies entering the metabolic dysfunction-associated steatohepatitis arena.

Ensuring product quality remains at the forefront. This issue’s European Regulatory Watch details Europe’s strategy to become an attractive location for life sciences innovation, and the Ask the Expert feature outlines best practices for implementing contamination control strategies.

On the manufacturing front, “Keys to Navigating the Complex Drug Supply Chain” shows how digital tools help manufacturers adapt to ongoing global volatility.

As a whole, this issue reveals an industry strengthening its foundation while embracing innovation. Success now demands not just advanced tools and processes, but collaboration, resilience, and a focus on improving outcomes for patients worldwide.

Pharmaceutical innovation is a complex journey shaped by scientific, technological, and market dynamics. Stakeholders must balance mastering fundamentals with adopting new tools and approaches. Insights from Aragen Life Sciences highlight the impact of digital tools and geopolitical changes on formulation decisions. Personalized therapies face scalability and regulatory challenges. R&D tax relief and new entrants in the metabolic dysfunction-associated steatohepatitis field are discussed. Europe's strategy for life sciences innovation and best practices for contamination control are outlined. Digital tools aid manufacturers in navigating the volatile drug supply chain.

Success depends on collaboration, resilience, and a focus on improving outcomes for patients worldwide.

Resilience and Precision in Pharma Development

The pharmaceutical industry is in a period of rapid transformation, driven by scientific innovation, regulatory expectations, and the increasing complexity of therapies. This issue highlights the most pressing trends shaping the sector and the strategies that organizations are adopting to stay competitive.

In our cover story, Susan Haigney explores innovative approaches to bioanalysis, in which automation and novel methodologies are expanding capabilities for faster and more reliable results. As the complexity of drug modalities increases, bioanalytical innovation is no longer optional; it is essential for ensuring product safety, regulatory compliance, and development speed.

Equally critical is formulation development. Cynthia Challener examines how artificial intelligence (AI) and machine learning are being applied to predictive modeling for small molecules, where drug candidates present formidable challenges in molecular complexity and delivery.

Advances in digitalization and automation of aseptic processing are helping organizations address the growing diversity of injectable drug products. Streamlined, technology-enabled approaches are reducing human intervention, improving sterility assurance, and enhancing scalability.

This issue also delves into mechanistic modeling of renal clearance, with Akanksha Prasad providing insights into optimizing dosing strategies for elderly patients. As patient populations age, this type of research is vital to balancing efficacy with safety in clinical care.

Data integration and digital transformation remain central to the industry’s progress. Jennifer Markarian highlights how better use of process data, enhanced by AI and advanced analytics, is enabling smarter process control and more connected manufacturing systems.

Patrick Lavery examines FDA’s push for greater quality, integrity, and uniformity, particularly in the context of advanced manufacturing and batch control. Our Ask the Expert section takes a look at the importance of real-world evidence used in pharmacovigilance.

As these articles show, the future of pharma lies in a careful balance: adopting cutting-edge technologies while upholding rigorous standards of quality and safety. The organizations that succeed will be those that embrace innovation while keeping patients at the center of every decision.

When referring to this article, please cite it as Hennessy, M. From Discovery to Delivery: Evolving Practices in Pharma. 

The pharmaceutical industry is undergoing rapid transformation due to scientific innovation, regulatory demands, and complex therapies. Key trends include bioanalytical advancements, AI in formulation development, and digitalization in aseptic processing. These innovations are crucial for ensuring safety, compliance, and efficiency. Mechanistic modeling is optimizing dosing for aging populations, while data integration enhances process control. The FDA emphasizes quality and uniformity in advanced manufacturing. Success in the industry hinges on adopting new technologies while maintaining high standards of quality and patient-centered care.

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.

From Discovery to Delivery: Evolving Practices in Pharma

® captures the state of that journey, one that is as much about mastering fundamentals as it is about embracing new tools and approaches.

Our cover story, “The Evolving Science Behind Formulation Development,” explores strategies across the drug product lifecycle. Vaibhav Sihorkar, PhD, of Aragen Life Sciences, offers insights into problem solving, the role of digital tools, and how geopolitical change is influencing formulation decisions from a CRDMO’s perspective. The complex area of drug formulation is further explored in Cynthia Challener’s “Personalized and Patient-Centric Administration of Oral Medicines,” which highlights how individualized therapies are moving forward despite the challenges of scalability and regulation.

Ensuring product quality remains at the forefront. In our Ask the Expert feature, Michelle Heiter and Susan J. Schniepp outline best practices for implementing contamination control strategies that safeguard patient safety and regulatory compliance. Meanwhile, the Pharma Fundamentals article by Evonne Brennan reinforces the essential skills professionals need to thrive in this rapidly changing field.

At the critical stage of technology transfer, “Emerging Tools, Integrated Controls Impact Tech Transfer” highlights how smarter systems can streamline the transition from lab to production. In advanced therapies, “Optimizing Testing in Cell and Gene Therapy” underscores the need for agile, compliant testing methods that can keep pace with accelerated development timelines. On the manufacturing front, Susan Haigney’s “Keys to Navigating the Complex Drug Supply Chain” shows how digital tools help manufacturers adapt to ongoing global volatility.

When referring to this article, please cite it has Hennessy, M. Building Resilience and Precision in Pharma Development. 

Pharmaceutical innovation is a complex journey shaped by scientific discovery, technological evolution, and market demands. This issue examines the evolving science of formulation development, emphasizing problem-solving, digital tools, and geopolitical influences. Personalized oral medicines face scalability and regulatory challenges. Contamination control strategies are crucial for product quality and regulatory compliance. Technology transfer benefits from integrated controls, while cell and gene therapy testing requires agile methods. Digital tools aid in navigating the drug supply chain amid global volatility. Success in the industry hinges on collaboration, resilience, and patient outcome improvement.

Scientific discovery, technological evolution, and market demands are constantly reshaping the landscape.

Building Resilience and Precision in Pharma Development

As you read this note, pharmaceutical development and manufacturing are being redefined by collaboration, innovation, and the urgent need for agility. The throughline across this issue of 

® is unmistakable: success now depends on integration of systems, data, partnerships, and people.

Our cover story, “Customizable Relationships Enhance Speed to Market,” underscores this reality. As drug modalities become more complex, sponsor companies and CDMOs are moving away from traditional, transactional relationships. The new model is one of shared risk and long-term collaboration, driven by mutual investment in speed, quality, and innovation.

This spirit of innovation is reflected in the development space, where ocular drug delivery continues to challenge formulation scientists. As Cynthia Challener reports in “Advanced Solutions for Sustained Delivery of Ocular Therapies,” sustained-release technologies for eye care are gaining traction, improving compliance and outcomes in an area in which frequent dosing has long been a barrier.

“In-line UV Spectrometry Monitoring in Cleaning Validation” offers a timely look at how Pharma 4.0 principles are reshaping validation. The integration of in-line analytical tools enables real-time monitoring, greater data reliability, and stronger alignment with quality-by-design and digital manufacturing goals.

On the analytics front, “Overcoming PK/PD Modeling Challenges” explores how AI and machine learning are transforming PK/PD modeling. These tools enable faster, more accurate predictions of drug behavior, helping teams avoid costly delays and unnecessary experimentation.

We also examine the realities of small-batch fill/finish operations, including the technologies and process solutions emerging to meet the demands of low-volume, high-value production.

Finally, in “ICH Q12 and Post-Approval Changes,” Siegfried Schmitt sheds light on why streamlined post-approval change management remains elusive, and why it’s crucial for maintaining supply resilience.

Taken together, these articles offer a clear view of where pharmaceutical manufacturing is headed: toward smarter tools, deeper partnerships, and a renewed focus on compliance and quality at every stage of the product lifecycle.

®
Vol. 49, No. 6
July/August 2025
Page: 8

When referring to this article, please cite it as Hennessy, M. The Future of Pharma: Connected, Continuous, and Compliant. 

Pharmaceutical development and manufacturing are evolving through collaboration, innovation, and agility. Success now hinges on integrating systems, data, partnerships, and people. The shift from traditional, transactional relationships to shared risk and long-term collaboration is crucial, especially as drug modalities grow more complex. Innovations in ocular drug delivery, in-line UV spectrometry for cleaning validation, and AI-driven PK/PD modeling are reshaping the industry. Small-batch fill/finish operations and streamlined post-approval change management are also critical for maintaining supply resilience and ensuring quality throughout the product lifecycle.

Pharma manufacturing is headed toward smarter tools, deeper partnerships, and a renewed focus on compliance and quality at every stage of the product lifecycle.